Business
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum
Patent Expands Protection for the Company’s RenovoCath Device, the Novel Dual-Occlusion Catheter-Based System RenovoRx Currently Holds a Strong and Growing
About this update from Renovorx, Inc.
[{"type":"text","content":"Patent Expands Protection for the Company’s RenovoCath Device, the Novel Dual-Occlusion Catheter-Based System RenovoRx Currently Holds a Strong and Growing Global Intellectual Property Portfolio with 19 Issued or Allowed Patents and 14 Pending Patents Supporting the Commercialization of the RenovoCath Device MOUNTAIN VIEW, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that the Japan Patent Office (JPO) has issued a Notice of Allowance for the Company’s first Japanese patent application (JP 2024-559262) titled “Method and Apparatus for Delivering an Agent Through the Vasa Vasorum.” This patent strengthens RenovoRx’s global intellectual property, supports the Company’s approach to targeted drug-delivery, and expands protection for its therapy platform in the strategically important Japanese market. The allowed claims of the patent protect the RenovoCath dual-occlusion catheter-based system equipped with integrated imaging and pressure-sensing technology that is designed to enable targeted localization and controlled infusion of drugs or biologics into targeted tissue via the vasa vasorum. The vasa vasorum are microscopic blood vessels that supply nutrients and oxygen to the walls of large arteries and provide access to the tissue outside the blood vessels. The ability to target therapeutic agents at this local level is a key attribute of RenovoCath; avoiding systemic dosing of therapeutics, such as intravenous (IV) chemotherapy, which can have debilitating side effects. “This Japanese patent allowance represents an important milestone in expanding RenovoRx’s global intellectual property footprint and underscores a significant advancement in targeted drug-delivery utilizing these micro vessels as a pathway to reach difficult-to-treat tumors,” said Shaun Bagai, Chief Executive Officer of RenovoRx. “By enabling drug-delivery of therapeutics directly near a tumor site, RenovoCath has the potential to improve clinical outcomes while minimizing systemic drug exposure in patients.” Mr. Bagai continued, “This patent reinforces the importance of the differentiated mechanism underlying our proprietary Trans-Arterial M...